Fingolimod leads to early clinical and MRI benefits in relapsing-remitting multiple sclerosis

被引：0
|
作者：
Chin, P.
von Rosenstiel, P.
Haering, D.
Francis, G.
Kappos, L.
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S70 / S71
页数：2
相关论文
共 50 条
  • [1] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [2] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [3] Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice
    Alcala-Vicente, Carmen
    Perez-Miralles, Francisco C.
    Gascon-Gimenez, Francisco
    Bosca-Blasco, Isabel
    Navarre-Gimeno, Arantxa
    Coret-Ferrer, Francisco
    Casanova-Estruch, Bonaventura
    REVISTA DE NEUROLOGIA, 2017, 64 (10) : 445 - 453
  • [4] Effects of fingolimod in relapsing-remitting multiple sclerosis Comment
    Sorensen, Per Soelberg
    LANCET NEUROLOGY, 2014, 13 (06): : 526 - 527
  • [5] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Vosiliou, S.
    DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
  • [6] Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients
    Cannizzaro, Miryam
    Ferre, Laura
    Clarelli, Ferdinando
    Giordano, Antonino
    Sangalli, Francesca
    Colombo, Bruno
    Comi, Giancarlo
    Moiola, Lucia
    Martinelli, Vittorio
    Filippi, Massimo
    Esposito, Federica
    JOURNAL OF NEUROLOGY, 2022, 269 (10) : 5596 - 5605
  • [7] Effectiveness of fingolimod in Spanish patients with relapsing-remitting multiple sclerosis in the clinical practice
    Meca-Lallana, V.
    Martinez Yelamos, S.
    Mallada, J.
    Meca-Lallana, J.
    Martinez, M.
    Marzo, E.
    Duran, C.
    Ayuso, T.
    Barrero, F.
    Romero, R.
    Guillen, R.
    Ricart, J.
    Garcia, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 855 - 855
  • [8] Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
    Gajofatto, Alberto
    Turatti, Marco
    Monaco, Salvatore
    Benedetti, Maria Donata
    DRUG HEALTHCARE AND PATIENT SAFETY, 2015, 7 : 157 - 167
  • [9] The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis
    Sirito, Tommaso
    Boffa, Giacomo
    Lapucci, Caterina
    Boccia, Vincenzo Daniele
    Aluan, Kenda
    Roccatagliata, Luca
    Uccelli, Antonio
    Laroni, Alice
    Capello, Elisabetta
    Cellerino, Maria
    Inglese, Matilde
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 601 - 602
  • [10] Pharmacogenomic predictors of fingolimod response in relapsing-remitting multiple sclerosis
    Campagna, M. P.
    Stankovich, J.
    Zhong, M.
    Kleinova, P.
    Matesanz, F.
    Eichau, S.
    Slee, M.
    Kilpatrick, T.
    Kubala Havrdova, E.
    Izquierdo, G.
    Patsopoulos, N.
    Lea, R.
    Lechner-Scott, J.
    Butzkueven, H.
    Jokubaitis, V.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 660 - 661
12345